DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells

Vaccine

Volumn 28, Issue 45, 2010, Pages 7297-7305

  Kim, Daejin ^a,b   Hung, Chien Fu ^c   Wu, T C ^c   Park, Yeong Min ^d  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d Pusan National University School of Medicine   (South Korea)

Author keywords

Galactosylceramide; Anti tumor immunity; DNA vaccine

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTINEOPLASTIC AGENT; ARGINYLALANYLHISTIDYLTYROSYLASPARAGINYLISOLEUCYLVALYLTHREONYLPHENYLALANINE; DNA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; SPLEEN; VACCINES, DNA;

EID: 77957749282     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.079     Document Type: Article

References (41)

1. Liu M.A. DNA vaccines: a review. J Intern Med 2003, 253:402-410.
2. Boyd D., Hung C.F., Wu T.C. DNA vaccines for cancer. IDrugs 2003, 6:1155-1164.
3. Nichols W.W., Ledwith B.J., Manam S.V., Troilo P.J. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 2001, 772:30-39.
4. Shan Lu Immunogenicity of DNA vaccines in humans. Human Vaccines 2008, 4(6):449-452.
5. Tarte K., Klein B. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 1999, 13:653-663.
6. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003, 3:630-641.
7. Doan Tracy, Herd Karen A., Lambert Paul F., Fernando Germain J.P., Street Michael D., Tindle Robert W. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res 2000, 60:2810-2815.
8. Jiang X.B., Lu X.L., Hu P., Liu R.E. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 2009, 27:6210-6216.
9. Hung C.F., Wu T.C., Monie A., Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev 2008, 222:43-69.
10. Kim T.G., Kim C.H., Won E.H., Bae S.M., Ahn W.S., Park J.B., et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 2004, 112:117-125.
11. Helson R., Olszewska W., Singh M., Megede J.Z., Melero J.A., O'Hagan D., et al. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. Vaccine 2008, 26:753-761.
12. Huang Y., Chen A., Li X., Chen Z., Zhang W., Song Y., et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine 2008, 26:1807-1816.
13. Burdin N., Brossay L., Koezuka Y., Smiley S.T., Grusby M.J., Gui M., et al. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 1998, 161:3271-3281.
14. Spada F.M., Koezuka Y., Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998, 188:1529-1534.
15. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
16. Shimizu K., Kurosawa Y., Taniguchi M., Steinman R.M., Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007, 204:2641-2653.
17. Chung Y., Qin H., Kang C.Y., Kim S., Kwak L.W., Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007, 110:2013-2019.
18. Nagaraj S., Ziske C., Strehl J., Messmer D., Sauerbruch T., Schmidt-Wolf I.G. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int Immunol 2006, 18:1279-1283.
19. Fujii S., Shimizu K., Smith C., Bonifaz L., Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co administered protein. J Exp Med 2003, 198:267-279.
20. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
21. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001, 108:669-678.
22. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60:1035-1042.
23. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23:2242-2249.
24. Hung C.F., Cheng W.F., Hsu K.F., Chai C.Y., He L., Ling M., et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001, 61:3698-3703.
25. Donnelly J.J., Ulmer J.B., Liu M.A. DNA vaccines. Life Sci 1997, 60:163-172.
26. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18:927-974.
27. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., et al. CD1d-restricted and TCR-mediated activation of Vα14NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
28. Fujii S., Shimizu K., Kronenberg M., Steinman R.M. Prolonged IFN-γ-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002, 3:867-874.
29. Goldberg S.M., Bartido S.M., Gardner J.P., Guevara-Patiño J.A., Montgomery S.C., Perales M.A., et al. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res 2005, 11:8114-8121.
30. Motohashi S., Nagato K., Kunii N., Yamamoto H., Yamasaki K., Okita K., et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009, 182:2492-2501.
31. Kunii N., Horiguchi S., Motohashi S., Yamamoto H., Ueno N., Yamamoto S., et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009, 100:1092-1098.
32. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002, 195:617-624.
33. Parekh V.V., Wilson M.T., Olivares-Villagómez D., Singh A.K., Wu L., Wang C.R., et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005, 115:2572-2583.
34. Yi H., Rong Y., Yankai Z., Wentao L., Hongxia Z., Jie W., et al. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine 2006, 24:2575-2584.
35. Ferraz J.C., Stavropoulos E., Yang M., Coade S., Espitia C., Lowrie D.B., et al. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect Immun 2004, 72:6945-6950.
36. Santra S., Barouch D.H., Korioth-Schmitz B., Lord C.I., Krivulka G.R., Yu F., et al. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci USA 2004, 101:11088-11093.
37. Dupuis M., Denis-Mize K., Woo C., Goldbeck C., Selby M.J., Chen M., et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000, 165:2850-2858.
38. Chattergoon M.A., Kim J.J., Yang J.S., Robinson T.M., Lee D.J., Dentchev T., et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 2000, 18:974-979.
39. Rols M.P. Mechanism by which electroporation mediates DNA migration and entry into cells and targeted tissues. Methods Mol Biol 2008, 423:19-33.
40. Best S.R., Peng S., Juang C.M., Hung C.F., Hannaman D., Saunders J.R., et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27:5450-5459.
41. Whiteside T.L., Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 2004, 53:240-248.